Literature DB >> 14871649

Immunopathways in giant cell arteritis and polymyalgia rheumatica.

Cornelia M Weyand1, Wei Ma-Krupa, Jörg J Goronzy.   

Abstract

Giant cell arteritis (GCA), a vasculitis that targets medium- and large-size arteries, is ranked as a medical emergency because of its potential to cause blindness and stroke. The typical lesions, granulomas in the vessel wall, are formed by IFN-gamma-producing CD4+ T cells and macrophages. CD4+ T cells undergo in situ activation in the adventitia, where they interact with indigenous dendritic cells. Tissue injury is mediated by several distinct sets of macrophages that are committed to diverse effector functions. The dominant tissue injury in the media results from oxidative stress and leads to smooth muscle cell apoptosis and nitration of endothelial cells. Macrophage-derived growth factors are instrumental in driving the response-to-injury program of the artery that causes intimal hyperplasia and vessel occlusion. Clinical manifestations are those of tissue ischemia or a syndrome of exuberant systemic inflammation. The vascular and the systemic components of GCA contribute differentially to the disease, leading to distinct clinical phenotypes of this arteritis. Immunologically most interesting is polymyalgia rheumatica, in which the systemic component is combined with aborted vasculitis, suggesting a role for artery-specific tolerance mechanisms.

Entities:  

Mesh:

Year:  2004        PMID: 14871649     DOI: 10.1016/S1568-9972(03)00064-8

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  26 in total

1.  Lower body mass index is associated with a higher risk of giant cell arteritis: a systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Charat Thongprayoon; Kenneth J Warrington
Journal:  Ann Transl Med       Date:  2015-09

2.  Early menopause, low body mass index, and smoking are independent risk factors for developing giant cell arteritis.

Authors:  K Larsson; D Mellström; E Nordborg; C Nordborg; A Odén; E Nordborg
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

Review 3.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  Varicella zoster virus vasculopathy: analysis of virus-infected arteries.

Authors:  M A Nagel; I Traktinskiy; Y Azarkh; B Kleinschmidt-DeMasters; T Hedley-Whyte; A Russman; E M VanEgmond; K Stenmark; M Frid; R Mahalingam; M Wellish; A Choe; R Cordery-Cotter; R J Cohrs; D Gilden
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 5.  [Pathogenesis of medium- and large-vessel vasculitis].

Authors:  C M Weyand; J J Goronzy
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

Review 6.  Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis.

Authors:  N Maugeri; P Rovere-Querini; M Baldini; M G Sabbadini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

Review 7.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

8.  Statin use in giant cell arteritis: a retrospective study.

Authors:  Jean Schmidt; Tanaz A Kermani; Francesco Muratore; Cynthia S Crowson; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2013-04-01       Impact factor: 4.666

9.  Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis.

Authors:  Lindsay Lally; Alessandra Pernis; Navneet Narula; Wei-Ti Huang; Robert Spiera
Journal:  Rheumatology (Oxford)       Date:  2014-09-10       Impact factor: 7.580

10.  Cryptococcal Meningitis in A Patient With Giant Cell Arteritis.

Authors:  Jin Lv; Qiankun Zhang
Journal:  Arch Rheumatol       Date:  2017-04-04       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.